(Reuters) - The Food and Drug Administration in March slapped its strongest warning on the label of Aranesp and similar anemia drugs, calling on doctors to use the lowest dose that can effectively avoid the need for blood transfusions.
The new CMS reimbursement rules stipulate that cancer patients receiving chemotherapy should only initiate use of the medicines if their levels of hemoglobin -- the oxygen-carrying part of red blood cells -- fall below 10 milligrams per deciliter. They also limit the duration of EPO therapy to a maximum of eight weeks after completion of chemotherapy.
Read more at Reuters.com Government Filings News
The new CMS reimbursement rules stipulate that cancer patients receiving chemotherapy should only initiate use of the medicines if their levels of hemoglobin -- the oxygen-carrying part of red blood cells -- fall below 10 milligrams per deciliter. They also limit the duration of EPO therapy to a maximum of eight weeks after completion of chemotherapy.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment